Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.

A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00077987

Enrollment

Registered

2004-02-18

Start date

2003-12-31

Completion date

2005-04-30

Last updated

2007-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Brief summary

Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.

Interventions

DRUGSU011248

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Metastatic colorectal cancer * Failed selected cancer therapies in the past.

Exclusion criteria

* Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.

Design outcomes

Primary

Measure	Time frame
Anti-tumor efficacy	—

Secondary

Measure	Time frame
Tumor control survival safety	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026